Cogent Biosciences(COGT) - 2024 Q4 - Annual Results

Exhibit 99.1 https://files.reportify.cc/m Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results Top-line results from SUMMIT trial in NonAdvSM patients expected July 2025 Bezuclastinib – Gastrointestinal Stromal Tumors (GIST) • Report top-line results by the end of 2025 from the pivotal Phase 3 PEAK trial. PEAK is a global, blinded, randomized clinical trial studying the combination of bezuclastinib and sunitinib versus sunitinib alone in patients with ...